Townsquare Capital LLC Cuts Position in Thermo Fisher Scientific Inc. $TMO

Townsquare Capital LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 61.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,965 shares of the medical research company’s stock after selling 4,633 shares during the quarter. Townsquare Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,438,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in TMO. Financial Management Network Inc. boosted its position in Thermo Fisher Scientific by 3.7% in the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock valued at $248,000 after buying an additional 18 shares during the period. Bruce G. Allen Investments LLC increased its holdings in Thermo Fisher Scientific by 8.8% in the third quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company’s stock valued at $114,000 after buying an additional 19 shares during the last quarter. Elevation Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Finally, S.A. Mason LLC boosted its stake in Thermo Fisher Scientific by 7.0% in the third quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock valued at $155,000 after acquiring an additional 21 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $593.16 on Friday. The firm has a market cap of $222.86 billion, a PE ratio of 34.27, a P/E/G ratio of 3.99 and a beta of 0.91. The firm has a 50 day simple moving average of $594.14 and a 200-day simple moving average of $536.01. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.44 by $0.13. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has approved a stock buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were given a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Insider Activity

In related news, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the sale, the executive vice president directly owned 18,731 shares of the company’s stock, valued at $11,238,600. The trade was a 36.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the transaction, the vice president owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. The trade was a 7.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 124,517 shares of company stock valued at $72,363,568 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $6.57 vs. consensus ~$6.44 and revenue $12.21B vs. ~$11.95B, showing 7% sales growth and reinforcing demand from pharma and life‑sciences customers. Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management disclosed potential EPS upside from the Clario deal, which could be accretive and support longer‑term earnings growth if integration goes as planned. Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
• Positive Sentiment: Some analysts remain bullish — William Blair maintained a Buy on TMO, citing resilient organic growth and stabilizing end markets. Thermo Fisher Scientific: Resilient Organic Growth and Stabilizing End-Markets Support Sustained Buy Rating
• Neutral Sentiment: Investor presentation and earnings call provide detail on segment performance, but no near-term catalytic change was signaled beyond the guidance update. Thermo Fisher Scientific Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: FY2026 guidance came in cautious: EPS $24.220–24.800 (vs. consensus ~24.64) and revenue $46.3B–$47.2B (vs. consensus ~46.5B), implying only 4%–6% growth and modest organic demand — investors focused on the conservative tone. Thermo Fisher stock slides on cautious profit guidance
• Negative Sentiment: Management signaled margin pressure and cautious profit expectations for 2026, which pressured the stock despite the Q4 beat. Thermo Fisher slips after issuing 2026 outlook (update)

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Barclays set a $650.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “overweight” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Wells Fargo & Company upped their price target on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Finally, Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $626.79.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.